Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

Computer and decision making.

Quantum Machine Learning for Drug–Target Interaction Prediction: A Hybrid Variational Circuit Approach on NISQ Hardware

Cherukuri Anusha, Dr. D. Radha, Sailaja Mattaparthi, B. Ratnamala, B.Giridhar

Published Nov 4, 2026• 0 citations
PDF (CC BY)Publisher

Abstract

Large compound libraries are reduced to candidate’s worth testing by computational prediction of drug-target interactions (DTI). We investigate whether this effort is aided by variational quantum circuits appropriate for noisy intermediate-scale quantum (NISQ) devices. Our hybrid model uses classical networks to encode ECFP4 fingerprints and protein sequence descriptors, compresses them to eight rotation angles, and then processes them using a four-layer hardware-efficient circuit that is read out using local Pauli-Z expectations. Realistic noise models are used to simulate the circuits, and it is trained end-to-end using gradients that match the parameter-shift algorithm. The model achieved test AUROCs of 0.896, 0.892, 0.911, and 0.878 on Davis, KIBA, BindingDB, and BIOSNAP. These results outperform a kernel SVM and logistic regression, although they lag behind a graph network on three datasets, a deep network (0.915–0.927), and gradient-boosted trees. Removing entanglement had little effect on the performance of a parameter-matched classical head, and no low-data advantage emerged. Hardware tolerance was demonstrated by the circuit itself. Because ranking is invariant to uniform noise attenuation, local readout avoided barren plateaus, 256 shots were sufficient, and 1% two-qubit error cost only 0.0025 AUROC. Calibration was recovered by recalibrating the reading. Hardware training costs, not noise, are the binding restriction. For drug-screening decisions, these predictions provide an evidence-based ranking of candidate compound–target pairs for experimental follow-up. The comparison with classical methods indicates whether adding a quantum circuit is justified by the resulting predictive performance and computational cost.

DOI
10.1922/comdem.v3i6s.18924

Related papers

Variational Quantum Regression for Binding Affinity Prediction: A Hybrid Quantum-Classical Framework with Explainable Molecular Descriptors

Volkan Erol

Predicting drug-target binding affinity with limited training data remains a central challenge in computational drug discovery. We introduce a hybrid quantum-classical framework combining molecular descriptors with variational quantum circuits for interpretable binding affinity prediction. Seven physicochemical descriptors (MW, logP, TPSA, HBD/HBA, rotatable bonds, aromatic rings) were encoded into 6-qubit variational circuits using parameterized rotations and controlled-Z entanglement. Quantum kernels were extracted and used for regression on 1,200 BindingDB molecules across kinase, GPCR, and protease targets, with external validation on 300 ChEMBL compounds. Performance was compared against SVR, random forest, gradient boosting, and neural network baselines using 100-fold bootstrap validation. Variational quantum regression achieved MSE = 0.056 ± 0.009, outperforming SVR by 32% (0.082 ± 0.013), RF by 28%, and GBM by 24%. Quantum advantage was most significant in low-data regimes (n < 500), where VQR maintained R2 > 0.85 versus R2 < 0.72 for classical methods. External validation confirmed generalization (R2 = 0.83). Our Explainable Quantum Pharmacology framework revealed TPSA and logP as dominant predictive features through gradientbased sensitivity analysis, aligning with established medicinal chemistry principles. Quantum kernels provide measurable, chemically interpretable improvements for molecular property prediction in data-limited scenarios. This work demonstrates practical quantum advantage for early-stage drug discovery applications on near-term quantum hardware.

•Oct 20, 2025•1 citation

A Hybrid Quantum-classical Fusion Neural Network to Improve Protein-ligand Binding Affinity Predictions for Drug Discovery

Laia Domingo, Mahdi M. Chehimi, S. Banerjee +7 more

Drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins that influence disease progression, which is financially and computationally demanding. Although classical and hybrid quantum machine learning models have been employed in previous studies to aid in binding affinity prediction, they encounter several issues related to convergence stability and prediction accuracy. In this regard, this paper introduces a novel hybrid quantum-classical deep learning model tailored for binding affinity prediction in drug discovery. Specifically, the proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum circuit architecture. Simulation results demonstrate a 6% improvement in prediction accuracy relative to existing classical models, as well as a significantly more stable convergence performance compared to previous classical approaches. Moreover, to scalably deploy the proposed framework over today's noisy intermediate-scale quantum (NISQ) devices, a novel quantum error mitigation algorithm is proposed. This algorithm outperforms existing techniques and is capable of mitigating errors with gate noise probabilities,$p \leq 0.05$, while resulting in no additional overhead during the training and testing phases.

arXiv:2309.03919•IEEE International Conference on Quantum Computing and Engineering (QCE)•Sep 15, 2024•23 citations

Representational efficiency and noise robustness in hybrid quantum-classical graph neural networks

Istiyak Amin Santo, Hasanul Bannah, Md Serajun Nabi +1 more

A central question in hybrid quantum–classical learning is whether variational quantum circuits (VQCs) preserve task-relevant information more efficiently than classical nonlinearities of equal output dimension. We study this question for drug–target interaction prediction in Alzheimer’s disease drug-repurposing workflows using a Hybrid Quantum–Classical Graph Neural Network (HQGNN). The model compresses 512-dimensional GNN embeddings into a four-qubit VQC (128 $$\times $$ compression) before a classical prediction head. On the DAVIS kinase benchmark, HQGNN achieves concordance index (CI) $$=0.527$$ and root mean squared error (RMSE) $$=0.850$$ , outperforming a dimension-matched classical bottleneck baseline (CI $$=0.500$$ ; random ranking). Under the same compression, the quantum layer recovers 51% of the ranking signal lost by compression relative to the full classical model and yields a 5.4% relative CI gain over the classical bottleneck. This effect is obtained with 24 trainable quantum parameters (representational yield $$\Delta $$ CI/parameter $$\approx 1.13\times 10^{-3}$$ ). Under depolarizing noise, RMSE degradation remains below 3.3% at realistic noisy intermediate-scale quantum (NISQ) levels ( $$p \le 0.01$$ ). Because the present benchmark is evaluated on a single transductive split, these results are interpreted as controlled proof-of-concept evidence of representational efficiency rather than definitive deployment-level generalization.

Discover Quantum Science•Jul 23, 2026•0 citations

Variational Quantum Machine Learning for Binary Classification on NISQ Hardware: Expressibility, Trainability, and Noise Robustness

Priya S. Mehta, Aleksandr V. Korolev

This study investigates classification performance and trainability of variational quantum classifiers on near-term noisy quantum hardware across circuit depth and qubit count regimes within the context of quantum computing and machine learning, an area of growing scientific importance given its implications for hybrid quantum-classical algorithm design and practical NISQ hardware benchmarking for near-term quantum advantage assessment. Using gradient-based parameter optimization of parameterized quantum circuits with hardware noise modeling via density matrix simulation and physical execution on IBM Eagle processors, we examine expressibility of parameterized circuits enabling nonlinear decision boundaries in feature Hilbert space, with trainability constrained by barren plateau gradients at large qubit counts in 96 circuit architectures (4 qubit counts x 4 depths x 6 ansatz families) evaluated across 5 classification datasets with 20 random initialization seeds each drawn from IBM Quantum Eagle (127-qubit) and Falcon (27-qubit) processors with noise mitigation via zero-noise extrapolation. Results indicate that 10-qubit, 4-layer VQC achieves 84.2% classification accuracy on the best benchmark, within 3.8 percentage points of classical SVM, but gradient variance decays exponentially with qubit count (variance halving per 2 added qubits), confirming barren plateau scaling (p < 0.001), with 84.2% accuracy, 3.8 pp gap to classical SVM baseline as the primary quantitative benchmark. Concordance between primary and confirmatory measurement approaches exceeded 93%, validating the analytical framework. These findings contribute empirically to quantum computing and machine learning and carry actionable implications for the design of programs and policies targeting hybrid quantum-classical algorithm design and practical NISQ hardware benchmarking for near-term quantum advantage assessment.

Princeton Journal of Pre-Collegiate Research•Jan 1, 2021•0 citations

Drug Target Interaction prediction using Variational Quantum classifier

Dassen Sathan, Shakuntala Baichoo

The need to discover therapeutic compounds has intensified in recent years due to the rise of antibiotic resistance and complexity of modern diseases. The conventional drug discovery pipeline is resource-intensive. The field of drug development has evolved into interdisciplinary science. Several computational techniques have been devised to assist researchers, in the identification of new drugs. These tools often employ machine learning algorithms that are typically executed on classical computing machines. However, recent advancements in the field of quantum computing have offered new possibilities to improve machine learning models. Quantum computing leverages unique quantum-mechanical characteristics to achieve more efficient computations. In this paper, we introduce a framework that utilizes Variational Quantum Classifier (VQC) techniques for the classification of drug-protein interactions, as shown in Figure 1. This approach exploit quantum computing to produce better results than classical computing methods. To validate the efficacy of our proposed framework, we utilized the KIBA dataset to assess the drug-target affinity score. The model was trained at a learning rate of 0.0001 over 500. Through a 3-fold cross-validation, we achieved a concordance index (CI) of 0.802. This performance surpasses that of linear regression technique (kronLRS), which has a concordance index of 0.68 and is comparable to deep learning methods, such as DeepCPI and DeepDTA, which have a CI of 0.86. Notably, standard VQC methods typically attain a CI of approximately 0.75, which is a metric that can be further optimized by adjusting the number of qubits or wires in the circuit.

International Conference on Next Generation Computing Applications (NextComp)•Oct 24, 2024•4 citations

Hybrid quantum neural networks for efficient protein-ligand binding affinity prediction

Seon-Geun Jeong, Kyeong-Hwan Moon, Won–Joo Hwang

Protein-ligand binding affinity is critical in drug discovery, but experimentally determining it is time-consuming and expensive. Artificial intelligence (AI) has been used to predict binding affinity, significantly accelerating this process. However, the high-performance requirements and vast datasets involved in affinity prediction demand increasingly large AI models, requiring substantial computational resources and training time. Quantum machine learning has emerged as a promising solution to these challenges. In particular, hybrid quantum-classical models can reduce the number of parameters while maintaining or improving performance compared to classical counterparts. Despite these advantages, challenges persist: why hybrid quantum models achieve these benefits, whether quantum neural networks (QNNs) can replace classical neural networks, and whether such models are feasible on noisy intermediate-scale quantum (NISQ) devices. This study addresses these challenges by proposing a hybrid quantum neural network (HQNN) that empirically demonstrates the capability to approximate non-linear functions in the latent feature space derived from classical embedding. The primary goal of this study is to achieve a parameter-efficient model in binding affinity prediction while ensuring feasibility on NISQ devices. Numerical results indicate that HQNN achieves comparable or superior performance and parameter efficiency compared to classical neural networks, underscoring its potential as a viable replacement. This study highlights the potential of hybrid QML in computational drug discovery, offering insights into its applicability and advantages in addressing the computational challenges of protein-ligand binding affinity prediction.

arXiv:2509.11046•EPJ Quantum Technology•Oct 22, 2025•5 citations
Large compound libraries are reduced to candidate’s worth testing by computational prediction of drug-target interactions (DTI). We investigate whether this effort is aided by variational quantum circuits appropriate for noisy intermediate-scale quantum (NISQ) devices. Our hybrid model uses classical networks to encode ECFP4 fingerprints and protein sequence descriptors, compresses them to eight rotation angles, and then processes them using a four-layer hardware-efficient circuit that is read out using local Pauli-Z expectations. Realistic noise models are used to simulate the circuits, and it is trained end-to-end using gradients that match the parameter-shift algorithm. The model achieved test AUROCs of 0.896, 0.892, 0.911, and 0.878 on Davis, KIBA, BindingDB, and BIOSNAP. These results outperform a kernel SVM and logistic regression, although they lag behind a graph network on three datasets, a deep network (0.915–0.927), and gradient-boosted trees. Removing entanglement had little effect on the performance of a parameter-matched classical head, and no low-data advantage emerged. Hardware tolerance was demonstrated by the circuit itself. Because ranking is invariant to uniform noise attenuation, local readout avoided barren plateaus, 256 shots were sufficient, and 1% two-qubit error cost only 0.0025 AUROC. Calibration was recovered by recalibrating the reading. Hardware training costs, not noise, are the binding restriction. For drug-screening decisions, these predictions provide an evidence-based ranking of candidate compound–target pairs for experimental follow-up. The comparison with classical methods indicates whether adding a quantum circuit is justified by the resulting predictive performance and computational cost.
Predicting drug-target binding affinity with limited training data remains a central challenge in computational drug discovery. We introduce a hybrid quantum-classical framework combining molecular descriptors with variational quantum circuits for interpretable binding affinity prediction. Seven physicochemical descriptors (MW, logP, TPSA, HBD/HBA, rotatable bonds, aromatic rings) were encoded into 6-qubit variational circuits using parameterized rotations and controlled-Z entanglement. Quantum kernels were extracted and used for regression on 1,200 BindingDB molecules across kinase, GPCR, and protease targets, with external validation on 300 ChEMBL compounds. Performance was compared against SVR, random forest, gradient boosting, and neural network baselines using 100-fold bootstrap validation. Variational quantum regression achieved MSE = 0.056 ± 0.009, outperforming SVR by 32% (0.082 ± 0.013), RF by 28%, and GBM by 24%. Quantum advantage was most significant in low-data regimes (n < 500), where VQR maintained R2 > 0.85 versus R2 < 0.72 for classical methods. External validation confirmed generalization (R2 = 0.83). Our Explainable Quantum Pharmacology framework revealed TPSA and logP as dominant predictive features through gradientbased sensitivity analysis, aligning with established medicinal chemistry principles. Quantum kernels provide measurable, chemically interpretable improvements for molecular property prediction in data-limited scenarios. This work demonstrates practical quantum advantage for early-stage drug discovery applications on near-term quantum hardware.
Drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins that influence disease progression, which is financially and computationally demanding. Although classical and hybrid quantum machine learning models have been employed in previous studies to aid in binding affinity prediction, they encounter several issues related to convergence stability and prediction accuracy. In this regard, this paper introduces a novel hybrid quantum-classical deep learning model tailored for binding affinity prediction in drug discovery. Specifically, the proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum circuit architecture. Simulation results demonstrate a 6% improvement in prediction accuracy relative to existing classical models, as well as a significantly more stable convergence performance compared to previous classical approaches. Moreover, to scalably deploy the proposed framework over today's noisy intermediate-scale quantum (NISQ) devices, a novel quantum error mitigation algorithm is proposed. This algorithm outperforms existing techniques and is capable of mitigating errors with gate noise probabilities,p≤0.05p \leq 0.05p≤0.05, while resulting in no additional overhead during the training and testing phases.
A central question in hybrid quantum–classical learning is whether variational quantum circuits (VQCs) preserve task-relevant information more efficiently than classical nonlinearities of equal output dimension. We study this question for drug–target interaction prediction in Alzheimer’s disease drug-repurposing workflows using a Hybrid Quantum–Classical Graph Neural Network (HQGNN). The model compresses 512-dimensional GNN embeddings into a four-qubit VQC (128 ×\times × compression) before a classical prediction head. On the DAVIS kinase benchmark, HQGNN achieves concordance index (CI) =0.527=0.527=0.527 and root mean squared error (RMSE) =0.850=0.850=0.850 , outperforming a dimension-matched classical bottleneck baseline (CI =0.500=0.500=0.500 ; random ranking). Under the same compression, the quantum layer recovers 51% of the ranking signal lost by compression relative to the full classical model and yields a 5.4% relative CI gain over the classical bottleneck. This effect is obtained with 24 trainable quantum parameters (representational yield Δ\Delta Δ CI/parameter ≈1.13×10−3\approx 1.13\times 10^{-3}≈1.13×10−3 ). Under depolarizing noise, RMSE degradation remains below 3.3% at realistic noisy intermediate-scale quantum (NISQ) levels ( p≤0.01p \le 0.01p≤0.01 ). Because the present benchmark is evaluated on a single transductive split, these results are interpreted as controlled proof-of-concept evidence of representational efficiency rather than definitive deployment-level generalization.
This study investigates classification performance and trainability of variational quantum classifiers on near-term noisy quantum hardware across circuit depth and qubit count regimes within the context of quantum computing and machine learning, an area of growing scientific importance given its implications for hybrid quantum-classical algorithm design and practical NISQ hardware benchmarking for near-term quantum advantage assessment. Using gradient-based parameter optimization of parameterized quantum circuits with hardware noise modeling via density matrix simulation and physical execution on IBM Eagle processors, we examine expressibility of parameterized circuits enabling nonlinear decision boundaries in feature Hilbert space, with trainability constrained by barren plateau gradients at large qubit counts in 96 circuit architectures (4 qubit counts x 4 depths x 6 ansatz families) evaluated across 5 classification datasets with 20 random initialization seeds each drawn from IBM Quantum Eagle (127-qubit) and Falcon (27-qubit) processors with noise mitigation via zero-noise extrapolation. Results indicate that 10-qubit, 4-layer VQC achieves 84.2% classification accuracy on the best benchmark, within 3.8 percentage points of classical SVM, but gradient variance decays exponentially with qubit count (variance halving per 2 added qubits), confirming barren plateau scaling (p < 0.001), with 84.2% accuracy, 3.8 pp gap to classical SVM baseline as the primary quantitative benchmark. Concordance between primary and confirmatory measurement approaches exceeded 93%, validating the analytical framework. These findings contribute empirically to quantum computing and machine learning and carry actionable implications for the design of programs and policies targeting hybrid quantum-classical algorithm design and practical NISQ hardware benchmarking for near-term quantum advantage assessment.
The need to discover therapeutic compounds has intensified in recent years due to the rise of antibiotic resistance and complexity of modern diseases. The conventional drug discovery pipeline is resource-intensive. The field of drug development has evolved into interdisciplinary science. Several computational techniques have been devised to assist researchers, in the identification of new drugs. These tools often employ machine learning algorithms that are typically executed on classical computing machines. However, recent advancements in the field of quantum computing have offered new possibilities to improve machine learning models. Quantum computing leverages unique quantum-mechanical characteristics to achieve more efficient computations. In this paper, we introduce a framework that utilizes Variational Quantum Classifier (VQC) techniques for the classification of drug-protein interactions, as shown in Figure 1. This approach exploit quantum computing to produce better results than classical computing methods. To validate the efficacy of our proposed framework, we utilized the KIBA dataset to assess the drug-target affinity score. The model was trained at a learning rate of 0.0001 over 500. Through a 3-fold cross-validation, we achieved a concordance index (CI) of 0.802. This performance surpasses that of linear regression technique (kronLRS), which has a concordance index of 0.68 and is comparable to deep learning methods, such as DeepCPI and DeepDTA, which have a CI of 0.86. Notably, standard VQC methods typically attain a CI of approximately 0.75, which is a metric that can be further optimized by adjusting the number of qubits or wires in the circuit.
Protein-ligand binding affinity is critical in drug discovery, but experimentally determining it is time-consuming and expensive. Artificial intelligence (AI) has been used to predict binding affinity, significantly accelerating this process. However, the high-performance requirements and vast datasets involved in affinity prediction demand increasingly large AI models, requiring substantial computational resources and training time. Quantum machine learning has emerged as a promising solution to these challenges. In particular, hybrid quantum-classical models can reduce the number of parameters while maintaining or improving performance compared to classical counterparts. Despite these advantages, challenges persist: why hybrid quantum models achieve these benefits, whether quantum neural networks (QNNs) can replace classical neural networks, and whether such models are feasible on noisy intermediate-scale quantum (NISQ) devices. This study addresses these challenges by proposing a hybrid quantum neural network (HQNN) that empirically demonstrates the capability to approximate non-linear functions in the latent feature space derived from classical embedding. The primary goal of this study is to achieve a parameter-efficient model in binding affinity prediction while ensuring feasibility on NISQ devices. Numerical results indicate that HQNN achieves comparable or superior performance and parameter efficiency compared to classical neural networks, underscoring its potential as a viable replacement. This study highlights the potential of hybrid QML in computational drug discovery, offering insights into its applicability and advantages in addressing the computational challenges of protein-ligand binding affinity prediction.